Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis.

Caner Feyzi Demir Ferhat BALGETiR Ethemoglu Ozlem Dürdane Bekar Aksoy Filiz Demirdögen Suleyman Serdar Koca Mehmet Fatih Yetkin İrem Taşcı

Published in: Archives of rheumatology (2021)

Ocrelizumab therapy led to a prominent decrease in the frequency of FMF attacks, alleviated functional impairment, and improved quality of life in MS+FMF patients.

Keyphrases

multiple sclerosis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
mass spectrometry
peritoneal dialysis
stem cells
patient reported outcomes
bone marrow
patient reported